Ildong Holdings Co., Ltd. (KRX:000230)
6,470.00
-100.00 (-1.52%)
Last updated: Sep 1, 2026, 1:06 PM KST
Ildong Holdings Revenue
Ildong Holdings had revenue of 153.98B KRW in the quarter ending June 30, 2026, with 6.18% growth. This brings the company's revenue in the last twelve months to 607.65B, up 0.05% year-over-year. In the year 2025, Ildong Holdings had annual revenue of 590.89B, down -6.90%.
Revenue (ttm)
607.65B
Revenue Growth
+0.05%
P/S Ratio
0.12
Revenue / Employee
8.44B
Employees
72
Market Cap
74.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 590.89B | -43.76B | -6.90% |
| Dec 31, 2024 | 634.65B | -3.79B | -0.59% |
| Dec 31, 2023 | 638.45B | -37.09B | -5.49% |
| Dec 31, 2022 | 675.54B | 83.17B | 14.04% |
| Dec 31, 2021 | 592.37B | -4.09B | -0.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 630.89B |
| HANDOK | 560.89B |
| Kyongbo Pharmaceutical | 279.55B |
| HLB Pharmaceutical | 251.95B |
| Kukje Pharma | 181.27B |
| CKD Bio | 159.93B |
| Yuyu Pharma | 144.37B |
| CMG Pharmaceutical | 115.71B |